New anti-obesity medications are transforming weight management, challenging old paradigms, and raising new questions about the future of dieting and health.
A new study highlights the growing prevalence of extreme pediatric obesity in the U.S. and its association with serious metabolic and cardiovascular health risks, emphasizing the need for targeted interventions.
Scientists at KAIST have identified a unique gut-brain pathway that enables the brain to distinguish glucose from other nutrients, paving the way for novel treatments for metabolic disorders.
Recent research reveals glipizide, a common diabetes drug, increases cardiovascular risks compared to DPP-4 inhibitors. This challenges assumptions about sulfonylureas, urging personalized treatment considering heart health alongside glycemic control in type 2 diabetes management.